Cancer Advisor

OneDayMD  |  Integrative Oncology Review ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Updated: 15 June 2026 Case Series & Mechanistic Review Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort Last updated: 15 June 2026 DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated June 2026. Evidence Classification All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreati...

Quick Summary: The Patient Blueprint The National Comprehensive Cancer Network (NCCN) provides an authoritative guide to help patients understand pancreatic cancer care . Treatment decisions hinge primarily on resectability —whether the tumor can be cleanly removed by surgery. While surgery offers the best chance for long-term survival, optimal care almost always combines surgery with systemic treatments like chemotherapy and robust supportive care to manage weight loss, digestion, and pain. Receiving a pancreatic cancer diagnosis can feel overwhelming and fast-moving. To help you regain control, the National Comprehensive Cancer Network (NCCN) publishes standard-of-care updates specifically translated for patients and families. The pancreas is a dual-purpose organ: it produces digestive enzymes to break down food and releases hormones like insulin to regulate your blood sugar. When exocrine ...

Quick Summary & Core Update The American Society of Clinical Oncology (ASCO) has released its updated 2026 Living Guideline for Stage IV Non-Small Cell Lung Cancer (NSCLC) Without Driver Alterations . The major takeaway is the addition of retifanlimab-dlwr (an immunotherapy drug sold under the brand name ZYNYZ )  combined with standard chemotherapy as a highly effective first-line treatment option. Clinical trial data shows that adding this drug significantly extends survival and stalls cancer growth compared to chemotherapy alone. When dealing with a diagnosis of Stage IV Non-Small Cell Lung Cancer (NSCLC) , timing and precision are everything. Because lung cancer research moves incredibly fast, medical organizations utilize what are known as "Living Guidelines" —clinical roadmaps that experts update continuously as soon as groundbreaking clinical trial data breaks. The latest version,...